![Abin Thomas](https://profiles-cardiff.imgix.net/attachments/9772?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwyg
Rwy'n Gymrawd Ymchwil mewn Ystadegau yn y Ganolfan Ymchwil Treialon ym Mhrifysgol Caerdydd, lle rwy'n gweithio fel ystadegydd meddygol. Mae fy rôl yn cynnwys dylunio, cynnal, dadansoddi ac adrodd treialon rheoledig ar hap ac astudiaethau eraill sydd wedi'u cynllunio'n dda. Rwy'n canolbwyntio'n arbennig ar dreialon clinigol mewn haematoleg a chanser, yn ogystal ag ymchwil mewn iechyd amenedigol a meysydd iechyd cymhwysol eraill.
Mae fy nghefndir mewn bioystadegau, ac mae gen i arbenigedd mewn dadansoddi goroesi, modelu atchweliad, dulliau Bayesian, modelu rhagfynegol, a methodoleg treialon clinigol. Rwy'n cyfrannu at bob cam o ddatblygu a chyflwyno treialon, gan gynnwys datblygu protocol, cynlluniau dadansoddi ystadegol, adroddiadau, cyhoeddiadau, a cheisiadau grant. Yn ogystal, rwy'n cefnogi goruchwylio a mentora ystadegwyr iau ac yn cyfrannu at ymchwil methodolegol gydweithredol. Trwy fy ngwaith, rwy'n anelu at gymhwyso dulliau ystadegol cadarn i fynd i'r afael â chwestiynau clinigol pwysig a gwella canlyniadau cleifion.
Cyhoeddiad
2026
- Mehta, P. et al., 2026. CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial [Letter]. Leukemia & Lymphoma 67 (10), pp.2159-2163. (10.1080/10428194.2026.2690155)
- Knapper, S. et al. 2026. Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial. Blood (10.1182/blood.2025032681)
- Todd, S. et al., 2026. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Respiratory Medicine 14 (5), pp.417-431. (10.1016/S2213-2600(25)00433-3)
- Knapper, S. et al. 2026. CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial. Blood 147 (10), pp.1048-1057. (10.1182/blood.2025031006)
2025
- Russell, N. H. et al., 2025. Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML. Blood Advances 9 (24), pp.6455-6466. (10.1182/bloodadvances.2025017244)
- Van Der Maas, N. G. et al., 2025. A revised prognostic model for patients with acute myeloid leukemia and first relapse. Blood Advances 9 (15), pp.3853-3864. (10.1182/bloodadvances.2025015797)
- Potter, N. et al., 2025. Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. The Lancet Haematology 12 (5), pp.e346-e356. (10.1016/S2352-3026(25)00037-7)
- Russell, N. H. , Thomas, A. and Freeman, S. D. 2025. Reply to: Treatment intensification based on residual disease in elderly patients with AML. Journal of Clinical Oncology (10.1200/JCO-25-00198)
- Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)
- Aleem, A. et al., 2025. Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice. Clinical Lymphoma, Myeloma and Leukemia 25 (1), pp.50-56. (10.1016/j.clml.2024.08.006)
2024
- Versluis, J. et al., 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42 (34), pp.4084-4094. (10.1200/JCO.23.02631)
2023
- Freeman, S. D. et al., 2023. Fractionated versus single dose Gemtuzumab Ozogamicin with determinants of benefit in older AML: UK NCRI AML18 Trial. Blood 142 (20), pp.1697-1707. (10.1182/blood.2023020630)
- Knapper, S. et al., 2023. S131: a randomised assessment of the sequential addition of the kinase inhibitor Quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: results from the NCRI AML18 trial [Abstract]. HemaSphere 7 , pp.69-70. e0819670. (10.1097/01.hs9.0000967436.08196.70)
- Potter, N. et al., 2023. P503: a randomised trial of molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 studies. HemaSphere 7 , pp.857-858. e345570d. (10.1097/01.hs9.0000968920.34557.0d)
2022
- Russell, N. H. et al., 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107 (7), pp.1518-1527. (10.3324/haematol.2021.279010)
2021
- Tiong, I. S. et al., 2021. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances 5 (23), pp.5107-5111. (10.1182/bloodadvances.2021005455)
- Yousef, C. C. et al., 2021. Liraglutide effects on glycemic control and weight in patients with Type 2 Diabetes mellitus: a real-world, observational study and brief narrative review. Diabetes Research and Clinical Practice 177 108871. (10.1016/j.diabres.2021.108871)
- Nagraj, S. et al., 2021. Role of invasive mechanical ventilation and ECMO in the management of COVID-19: a systematic review. Indian Journal of Critical Care Medicine 25 (6), pp.691-698. (10.5005/jp-journals-10071-23870)
- AlAmmari, M. et al., 2021. The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population.. PLoS ONE 16 (5) e0250502. (10.1371/journal.pone.0250502)
- Esba, L. C. A. et al., 2021. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort sudy. Infectious Diseases and Therapy 10 , pp.253-268. (10.1007/s40121-020-00363-w)
- Ammari, M. A. et al., 2021. Mental health outcomes amongst health care workers during COVID 19 pandemic in Saudi Arabia. Frontiers in Psychiatry 11 619540. (10.3389/fpsyt.2020.619540)
2020
- Tiong, I. S. et al., 2020. The natural history of NPM1MUT Measurable Residual Disease (MRD) positivity after completion of chemotherapy in Acute Myeloid Leukemia (AML). Presented at: 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020) Virtual 5-8 December 2020. Vol. 136.Vol. Supple. American Society of Hematology. , pp.25-27. (10.1182/blood-2020-140296)
- Yousef, C. C. et al., 2020. Adoption of a personal health record in the digital age: Cross-sectional study. Journal of Medical Internet Research 22 (10) e22913. (10.2196/22913)
2019
- Alaskar, A. et al., 2019. Chemotherapy effect on fertility in male patients with Hodgkin and Non-Hodgkin Lymphoma. Presented at: 61st American Society of Hematology Annual Meeting & Exposition (ASH 2019) Orlando, FL, USA 07-10 December 2019. Vol. 134.Vol. S1. American Society of Hematology. , pp.5865. (10.1182/blood-2019-126447)
- Shaheeen, N. A. et al., 2019. Reducing defects in the datasets of clinical research studies: conformance with data quality metrics. BMC Medical Research Methodology 19 98. (10.1186/s12874-019-0735-7)
- Alotaibi, B. et al., 2019. Tuberculosis knowledge, attitude and practice among healthcare workers during the 2016 Hajj. PLoS ONE 14 (1) e0210913. (10.1371/journal.pone.0210913)
- Shaheen, N. A. et al., 2019. Paternal postnatal depression among fathers of newborn in Saudi Arabia. American Journal of Men's Health 13 (1), pp.1-12. (10.1177/1557988319831219)
Cynadleddau
- Tiong, I. S. et al., 2020. The natural history of NPM1MUT Measurable Residual Disease (MRD) positivity after completion of chemotherapy in Acute Myeloid Leukemia (AML). Presented at: 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020) Virtual 5-8 December 2020. Vol. 136.Vol. Supple. American Society of Hematology. , pp.25-27. (10.1182/blood-2020-140296)
- Alaskar, A. et al., 2019. Chemotherapy effect on fertility in male patients with Hodgkin and Non-Hodgkin Lymphoma. Presented at: 61st American Society of Hematology Annual Meeting & Exposition (ASH 2019) Orlando, FL, USA 07-10 December 2019. Vol. 134.Vol. S1. American Society of Hematology. , pp.5865. (10.1182/blood-2019-126447)
Erthyglau
- Mehta, P. et al., 2026. CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial [Letter]. Leukemia & Lymphoma 67 (10), pp.2159-2163. (10.1080/10428194.2026.2690155)
- Knapper, S. et al. 2026. Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial. Blood (10.1182/blood.2025032681)
- Todd, S. et al., 2026. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Respiratory Medicine 14 (5), pp.417-431. (10.1016/S2213-2600(25)00433-3)
- Knapper, S. et al. 2026. CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial. Blood 147 (10), pp.1048-1057. (10.1182/blood.2025031006)
- Russell, N. H. et al., 2025. Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML. Blood Advances 9 (24), pp.6455-6466. (10.1182/bloodadvances.2025017244)
- Van Der Maas, N. G. et al., 2025. A revised prognostic model for patients with acute myeloid leukemia and first relapse. Blood Advances 9 (15), pp.3853-3864. (10.1182/bloodadvances.2025015797)
- Potter, N. et al., 2025. Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. The Lancet Haematology 12 (5), pp.e346-e356. (10.1016/S2352-3026(25)00037-7)
- Russell, N. H. , Thomas, A. and Freeman, S. D. 2025. Reply to: Treatment intensification based on residual disease in elderly patients with AML. Journal of Clinical Oncology (10.1200/JCO-25-00198)
- Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)
- Aleem, A. et al., 2025. Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice. Clinical Lymphoma, Myeloma and Leukemia 25 (1), pp.50-56. (10.1016/j.clml.2024.08.006)
- Versluis, J. et al., 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42 (34), pp.4084-4094. (10.1200/JCO.23.02631)
- Freeman, S. D. et al., 2023. Fractionated versus single dose Gemtuzumab Ozogamicin with determinants of benefit in older AML: UK NCRI AML18 Trial. Blood 142 (20), pp.1697-1707. (10.1182/blood.2023020630)
- Knapper, S. et al., 2023. S131: a randomised assessment of the sequential addition of the kinase inhibitor Quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: results from the NCRI AML18 trial [Abstract]. HemaSphere 7 , pp.69-70. e0819670. (10.1097/01.hs9.0000967436.08196.70)
- Potter, N. et al., 2023. P503: a randomised trial of molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 studies. HemaSphere 7 , pp.857-858. e345570d. (10.1097/01.hs9.0000968920.34557.0d)
- Russell, N. H. et al., 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107 (7), pp.1518-1527. (10.3324/haematol.2021.279010)
- Tiong, I. S. et al., 2021. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances 5 (23), pp.5107-5111. (10.1182/bloodadvances.2021005455)
- Yousef, C. C. et al., 2021. Liraglutide effects on glycemic control and weight in patients with Type 2 Diabetes mellitus: a real-world, observational study and brief narrative review. Diabetes Research and Clinical Practice 177 108871. (10.1016/j.diabres.2021.108871)
- Nagraj, S. et al., 2021. Role of invasive mechanical ventilation and ECMO in the management of COVID-19: a systematic review. Indian Journal of Critical Care Medicine 25 (6), pp.691-698. (10.5005/jp-journals-10071-23870)
- AlAmmari, M. et al., 2021. The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population.. PLoS ONE 16 (5) e0250502. (10.1371/journal.pone.0250502)
- Esba, L. C. A. et al., 2021. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort sudy. Infectious Diseases and Therapy 10 , pp.253-268. (10.1007/s40121-020-00363-w)
- Ammari, M. A. et al., 2021. Mental health outcomes amongst health care workers during COVID 19 pandemic in Saudi Arabia. Frontiers in Psychiatry 11 619540. (10.3389/fpsyt.2020.619540)
- Yousef, C. C. et al., 2020. Adoption of a personal health record in the digital age: Cross-sectional study. Journal of Medical Internet Research 22 (10) e22913. (10.2196/22913)
- Shaheeen, N. A. et al., 2019. Reducing defects in the datasets of clinical research studies: conformance with data quality metrics. BMC Medical Research Methodology 19 98. (10.1186/s12874-019-0735-7)
- Alotaibi, B. et al., 2019. Tuberculosis knowledge, attitude and practice among healthcare workers during the 2016 Hajj. PLoS ONE 14 (1) e0210913. (10.1371/journal.pone.0210913)
- Shaheen, N. A. et al., 2019. Paternal postnatal depression among fathers of newborn in Saudi Arabia. American Journal of Men's Health 13 (1), pp.1-12. (10.1177/1557988319831219)